B7-H3 over expression in prostate cancer promotes tumor cell progression. 2011

Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
Department of Urology, First Affiliated Hospital of Soochow University and Institute of Medical Biotechnology, Soochow University, Suzhou, People's Republic of China.

OBJECTIVE We compared B7-H3 expression in benign prostatic hyperplasia and prostate cancer tissue specimens, and determined the effects of low B7-H3 expression on the PC-3 human prostate cancer cell line using RNA interference. METHODS B7-H3 expression in prostate specimens was determined by enzyme-linked immunosorbent assay. A PC-3 cell line with low B7-H3 expression was established by RNA interference to investigate the effect of B7-H3 on cell proliferation, adhesion, migration and invasion in vitro. RESULTS B7-H3 in tissue samples was significantly higher in the prostate cancer group than in the benign prostatic hyperplasia group (mean±SEM 174.73±56.80 vs 82.69±46.19 ng/gm, p<0.001). B7-H3 expression down-regulated by small interfering RNA decreased cell adhesion to PC-3 fibronectin more than 30%, and migration and Matrigel™ invasion up to 50%. No apparent impact was observed on cell proliferation. CONCLUSIONS B7-H3 is aberrantly expressed in prostate cancer. In addition to modulating tumor immunity, B7-H3 may have a novel role in regulating PC-3 cell progression.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D015703 Antigens, CD Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation. CD Antigen,Cluster of Differentiation Antigen,Cluster of Differentiation Marker,Differentiation Antigens, Leukocyte, Human,Leukocyte Differentiation Antigens, Human,Cluster of Differentiation Antigens,Cluster of Differentiation Markers,Antigen Cluster, Differentiation,Antigen, CD,CD Antigens,Differentiation Antigen Cluster,Differentiation Marker Cluster,Marker Cluster, Differentiation
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
February 2013, International journal of molecular medicine,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
January 2020, Technology in cancer research & treatment,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
March 2024, Translational oncology,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
October 2020, Pathology international,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
November 2014, Oncology reports,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
November 2018, Oncology reports,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
December 2012, The Journal of urology,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
October 2017, Oncology reports,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
December 2022, Oncology reports,
Hexing Yuan, and Xuedong Wei, and Guangbo Zhang, and Chen Li, and Xueguang Zhang, and Jianquan Hou
September 2017, Oncotarget,
Copied contents to your clipboard!